SAN DIEGO, June 17, 2014 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the JMP
Securities 2014 Healthcare Conference in New York, NY, on Tuesday, June 24, 2014 at 2:30 p.m. ET/11:30 a.m.
PT. David Ramsay,
Chief Financial Officer, will provide a corporate overview.
The presentation will be webcast through the "Investors" section
of Halozyme's corporate website at www.halozyme.com, and a
recording will be made available for 90 days following the event.
To access the live webcast, please log on to Halozyme's website
approximately 15 minutes prior to the presentation to register and
download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company
dedicated to developing and commercializing innovative products
that advance patient care. With a diversified portfolio of enzymes
that target the extracellular matrix, the Company's research
focuses primarily on a family of human enzymes, known as
hyaluronidases, which increase the dispersion and absorption of
biologics, drugs and fluids. Halozyme's pipeline addresses
therapeutic areas, including oncology, diabetes and dermatology
that have significant unmet medical need today. The Company markets
Hylenex® recombinant (hyaluronidase human
injection) and has partnerships with Roche, Pfizer and
Baxter. Halozyme is headquartered
in San Diego, CA. For more information on how we are
innovating, please visit our corporate website at
www.halozyme.com.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Denise
Powell
510-703-9491
dpowell@wcgworld.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
SOURCE Halozyme Therapeutics, Inc.